低剂量计量青作为癌症抗血管和抗炎策略
Hiroshi Kikuchi1,2, Nako Maishi1,3, Li Yu3
1Vascular Biology, Frontier Research Unit, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
British journal of cancer
|November 30, 2023
概括
低剂量计量学思丁 (LDM CDDP) 化疗通过抑制瘤生长和转移而没有诱导炎症,与传统的最大耐受剂量 (MTD) 化疗不同,显示出有前途.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 传统化疗使用最大耐受剂量 (MTD) 与无治疗间隔,可能导致血管生成和免疫抑制.
- 低剂量计量化学疗法 (LDM) 涉及频繁,低剂量,较少的炎症影响.
- 与MTD CDDP相比,LDM西斯普拉丁 (CDDP) 的疗效研究较少.
研究的目的:
- 与MTD CDDP相比,评估LDM CDDP在改变瘤内皮细胞表型方面的有效性.
- 研究LDMCDDP对瘤生长,转移,血管,免疫细胞和炎症的影响.
主要方法:
- 膀癌小鼠模型被用LDM或MTD凝胺 (GEM) 和CDDP治疗.
- 评估了瘤生长,转移,血管系统,免疫细胞透和炎症标志物.
- 组织学分析和mRNA表达被用来评估治疗效果.
主要成果:
- 与MTD CDDP + MTD GEM相比,LDM CDDP + MTD GEM在抑制瘤生长和骨转移方面表现出更好的表现.
- 在LDM中,CDDP降低了骨髓系衍生抑制细胞的积累.
- MTD CDDP诱导了瘤微环境中的炎症变化.
结论:
- LDM CDDP是一种有前途的化疗策略,因为它避免了与MTD CDDP相关的炎症变化.
- LDM CDDP,特别是结合起来,为癌症治疗提供了潜在的更有效和更少的炎症治疗方法.
相关概念视频
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
215
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
215
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
168
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
168